LAB Stock Overview
Develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Labiana Health, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.48 |
| 52 Week High | €3.18 |
| 52 Week Low | €1.09 |
| Beta | -0.48 |
| 11 Month Change | -11.43% |
| 3 Month Change | -12.68% |
| 1 Year Change | 93.75% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -46.09% |
Recent News & Updates
Shareholder Returns
| LAB | ES Pharmaceuticals | ES Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | 1.3% |
| 1Y | 93.8% | 14.8% | 29.5% |
Return vs Industry: LAB exceeded the Spanish Pharmaceuticals industry which returned 14.8% over the past year.
Return vs Market: LAB exceeded the Spanish Market which returned 29.5% over the past year.
Price Volatility
| LAB volatility | |
|---|---|
| LAB Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 2.9% |
| 10% most volatile stocks in ES Market | 5.4% |
| 10% least volatile stocks in ES Market | 0.6% |
Stable Share Price: LAB's share price has been volatile over the past 3 months compared to the Spanish market.
Volatility Over Time: LAB's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Spanish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 433 | Manuel Ortega | www.labiana.com |
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized, and biological formats; and Fosfomycin trometamol under the Fosfomicina Labiana brand name.
Labiana Health, S.A. Fundamentals Summary
| LAB fundamental statistics | |
|---|---|
| Market cap | €17.51m |
| Earnings (TTM) | -€4.42m |
| Revenue (TTM) | €59.70m |
0.3x
P/S Ratio-4.0x
P/E RatioIs LAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LAB income statement (TTM) | |
|---|---|
| Revenue | €59.70m |
| Cost of Revenue | €27.03m |
| Gross Profit | €32.67m |
| Other Expenses | €37.09m |
| Earnings | -€4.42m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 54.73% |
| Net Profit Margin | -7.41% |
| Debt/Equity Ratio | 1,180.3% |
How did LAB perform over the long term?
See historical performance and comparison